Cytek BioSciences Quarterly Balance Sheets Chart
Quarterly
|
Annual
Cytek BioSciences Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||
| current assets: | |||||||||||||||||
| cash and cash equivalents | 75,470,000 | 95,299,000 | 98,716,000 | 162,272,000 | 177,888,000 | 168,788,000 | 167,299,000 | 163,629,000 | 131,544,000 | 129,476,000 | 296,601,000 | 341,523,000 | 349,894,000 | 362,506,000 | 364,618,000 | 376,771,000 | 159,846,000 |
| restricted cash | 29,000 | 31,000 | 30,000 | 353,000 | 331,000 | 2,918,000 | 2,899,000 | ||||||||||
| marketable securities | 186,552,000 | 170,314,000 | 179,145,000 | 115,505,000 | 99,323,000 | 101,298,000 | 95,111,000 | 124,392,000 | 167,294,000 | 169,519,000 | 44,548,000 | ||||||
| trade accounts receivable | 56,232,000 | 55,029,000 | 60,588,000 | 52,634,000 | 44,643,000 | 50,306,000 | 55,928,000 | 55,402,000 | 49,624,000 | 43,100,000 | 48,864,000 | 39,636,000 | 36,811,000 | 30,406,000 | 29,760,000 | 29,450,000 | 24,029,000 |
| inventories | 49,487,000 | 45,347,000 | 43,893,000 | 46,800,000 | 50,070,000 | 54,742,000 | 60,877,000 | 66,875,000 | 65,731,000 | 69,502,000 | 48,154,000 | 49,369,000 | 45,345,000 | 37,982,000 | 32,171,000 | 27,511,000 | 26,655,000 |
| prepaid expenses and other current assets | 15,084,000 | 14,512,000 | 14,075,000 | 12,949,000 | 12,130,000 | 13,160,000 | 12,514,000 | 12,017,000 | 10,628,000 | 11,107,000 | 12,954,000 | 13,331,000 | 11,220,000 | 8,218,000 | 5,184,000 | 6,094,000 | 6,408,000 |
| total current assets | 382,825,000 | 380,501,000 | 396,446,000 | 390,191,000 | 384,084,000 | 388,647,000 | 392,060,000 | 422,315,000 | 424,821,000 | 425,622,000 | 454,020,000 | 443,859,000 | 443,270,000 | 439,112,000 | 431,733,000 | 439,826,000 | 216,938,000 |
| deferred income tax assets, noncurrent | 35,765,000 | 33,709,000 | 33,374,000 | 30,778,000 | 29,676,000 | 32,708,000 | 30,487,000 | 24,080,000 | 26,387,000 | 23,404,000 | 20,459,000 | 13,988,000 | 11,689,000 | 10,688,000 | 9,173,000 | 7,378,000 | 7,378,000 |
| property and equipment | 18,352,000 | 17,834,000 | 17,962,000 | 18,508,000 | 18,114,000 | 18,247,000 | 18,405,000 | 17,415,000 | 15,588,000 | 15,549,000 | 13,682,000 | 7,844,000 | 7,340,000 | 6,504,000 | 5,851,000 | 4,982,000 | 3,895,000 |
| operating lease right-of-use assets | 16,387,000 | 9,869,000 | 10,168,000 | 10,124,000 | 9,328,000 | 9,949,000 | 10,853,000 | 11,703,000 | 12,423,000 | 13,187,000 | 13,883,000 | 14,416,000 | 13,635,000 | 13,839,000 | |||
| goodwill | 16,707,000 | 16,678,000 | 16,663,000 | 16,183,000 | 16,183,000 | 16,183,000 | 16,183,000 | 16,457,000 | 19,143,000 | 19,143,000 | 10,144,000 | 10,144,000 | 10,144,000 | 10,144,000 | 10,144,000 | 476,000 | 476,000 |
| intangible assets | 18,601,000 | 19,431,000 | 20,128,000 | 20,492,000 | 21,420,000 | 22,252,000 | 23,084,000 | 24,292,000 | 23,683,000 | 24,664,000 | 4,331,000 | 4,485,000 | 3,859,000 | 4,328,000 | 4,739,000 | 361,000 | 333,000 |
| other noncurrent assets | 4,683,000 | 4,574,000 | 4,759,000 | 4,950,000 | 4,920,000 | 4,081,000 | 3,385,000 | 3,168,000 | 3,009,000 | 3,006,000 | 2,957,000 | 4,559,000 | 2,880,000 | 1,264,000 | 1,665,000 | 1,297,000 | 1,259,000 |
| total assets | 493,320,000 | 482,596,000 | 499,500,000 | 491,226,000 | 483,725,000 | 492,067,000 | 494,457,000 | 519,430,000 | 525,054,000 | 524,575,000 | 519,476,000 | 499,295,000 | 492,817,000 | 485,879,000 | 463,305,000 | 454,320,000 | 230,279,000 |
| liabilities and stockholders’ equity | |||||||||||||||||
| current liabilities: | |||||||||||||||||
| trade accounts payable | 6,853,000 | 6,247,000 | 5,529,000 | 5,389,000 | 3,191,000 | 3,725,000 | 3,032,000 | 4,711,000 | 3,082,000 | 5,280,000 | 4,805,000 | 5,640,000 | 6,749,000 | 5,971,000 | 3,034,000 | 3,927,000 | 3,324,000 |
| legal settlement liability, current | 1,968,000 | 1,705,000 | 1,705,000 | 2,496,000 | 2,503,000 | 2,550,000 | 2,561,000 | 2,600,000 | 1,918,000 | 1,906,000 | 2,163,000 | 2,175,000 | 2,139,000 | 1,554,000 | 1,463,000 | 7,405,000 | 7,229,000 |
| accrued expenses | 21,604,000 | 19,197,000 | 21,443,000 | 20,733,000 | 15,489,000 | 18,054,000 | 20,035,000 | 20,514,000 | 19,591,000 | 20,366,000 | 21,126,000 | 16,637,000 | 17,841,000 | 14,640,000 | 15,251,000 | 10,753,000 | 11,593,000 |
| other current liabilities | 14,717,000 | 12,836,000 | 13,494,000 | 8,814,000 | 7,228,000 | 8,228,000 | 7,903,000 | 7,821,000 | 8,388,000 | 10,861,000 | 7,960,000 | 4,949,000 | 5,630,000 | 8,386,000 | 6,352,000 | 2,044,000 | 1,351,000 |
| deferred revenue, current | 28,128,000 | 27,706,000 | 25,492,000 | 25,365,000 | 23,968,000 | 23,009,000 | 22,695,000 | 23,047,000 | 20,612,000 | 18,104,000 | 12,986,000 | 12,093,000 | 9,991,000 | 12,252,000 | 7,081,000 | 5,885,000 | 4,668,000 |
| total current liabilities | 73,270,000 | 67,691,000 | 67,663,000 | 62,797,000 | 52,379,000 | 55,566,000 | 56,226,000 | 58,693,000 | 53,591,000 | 56,517,000 | 49,040,000 | 41,494,000 | 42,350,000 | 42,803,000 | 33,181,000 | 30,014,000 | 28,165,000 |
| legal settlement liability, noncurrent | 8,477,000 | 8,819,000 | 9,036,000 | 17,066,000 | 16,912,000 | 16,722,000 | 16,477,000 | 16,095,000 | 16,462,000 | 16,045,000 | 15,596,000 | 15,122,000 | 14,649,000 | 14,635,000 | 13,745,000 | 12,633,000 | 11,724,000 |
| deferred revenue, noncurrent | 16,625,000 | 15,717,000 | 16,098,000 | 14,787,000 | 14,064,000 | 15,164,000 | 15,132,000 | 14,958,000 | 16,054,000 | 13,012,000 | 13,124,000 | 10,407,000 | 11,020,000 | 7,199,000 | 9,790,000 | 7,741,000 | 6,317,000 |
| operating lease liability, noncurrent | 14,119,000 | 7,448,000 | 7,552,000 | 7,756,000 | 8,113,000 | 8,697,000 | 9,479,000 | 10,139,000 | 10,833,000 | 11,541,000 | 12,312,000 | 14,326,000 | 12,316,000 | ||||
| long term debt | 791,000 | 918,000 | 1,050,000 | 1,236,000 | 1,330,000 | 1,477,000 | 1,648,000 | 1,736,000 | 1,882,000 | 2,133,000 | 2,271,000 | ||||||
| other noncurrent liabilities | 2,481,000 | 2,380,000 | 2,364,000 | 2,121,000 | 1,804,000 | 1,827,000 | 2,431,000 | 2,285,000 | 2,053,000 | 1,867,000 | 1,587,000 | 1,437,000 | 1,353,000 | 1,116,000 | 1,204,000 | 737,000 | 739,000 |
| total liabilities | 115,763,000 | 102,973,000 | 103,763,000 | 105,763,000 | 94,602,000 | 99,453,000 | 101,393,000 | 103,906,000 | 100,875,000 | 101,115,000 | 93,930,000 | 82,786,000 | 81,688,000 | 78,437,000 | 57,920,000 | 51,125,000 | 46,945,000 |
| commitments and contingencies | |||||||||||||||||
| stockholders’ equity: | |||||||||||||||||
| common stock | 127,000 | 128,000 | 129,000 | 130,000 | 132,000 | 131,000 | 131,000 | 136,000 | 136,000 | 136,000 | 135,000 | 135,000 | 135,000 | 134,000 | 126,000 | 125,000 | 24,000 |
| additional paid-in capital | 429,652,000 | 426,705,000 | 430,791,000 | 430,072,000 | 434,967,000 | 429,384,000 | 423,386,000 | 451,648,000 | 454,027,000 | 447,748,000 | 442,887,000 | 437,401,000 | 432,889,000 | 427,818,000 | 423,625,000 | 420,600,000 | 7,975,000 |
| accumulated deficit | -52,184,000 | -46,601,000 | -35,199,000 | -44,840,000 | -45,781,000 | -35,347,000 | -29,178,000 | -34,681,000 | -28,225,000 | -23,837,000 | -17,030,000 | -20,559,000 | -22,225,000 | -21,627,000 | -19,606,000 | -18,415,000 | -19,835,000 |
| accumulated other comprehensive gain | -38,000 | -609,000 | 16,000 | 101,000 | |||||||||||||
| total stockholders’ equity | 377,557,000 | 379,623,000 | 395,737,000 | 385,463,000 | 389,123,000 | 392,614,000 | 393,064,000 | 415,524,000 | 424,179,000 | 423,460,000 | 425,546,000 | 416,509,000 | 411,129,000 | 407,442,000 | 405,385,000 | 403,195,000 | |
| total liabilities and stockholders’ equity | 493,320,000 | 482,596,000 | 499,500,000 | 491,226,000 | 483,725,000 | 492,067,000 | 494,457,000 | 519,430,000 | 525,054,000 | 524,575,000 | |||||||
| accumulated other comprehensive loss | -195,000 | -1,554,000 | -1,275,000 | -1,579,000 | -1,759,000 | -587,000 | |||||||||||
| noncontrolling interest in consolidated subsidiary | 251,000 | 62,000 | 102,000 | 206,000 | 343,000 | 315,000 | 315,000 | ||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ equity | |||||||||||||||||
| accumulated other comprehensive income | -697,000 | -530,000 | 228,000 | 911,000 | 897,000 | 570,000 | 536,000 | ||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ equity | 519,476,000 | 499,295,000 | 492,817,000 | 485,879,000 | 463,305,000 | 454,320,000 | |||||||||||
| redeemable convertible preferred stock | 194,319,000 | ||||||||||||||||
| operating lease liability, non-current | 12,684,000 | ||||||||||||||||
| stockholders’ equity | |||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ deficit | |||||||||||||||||
| stockholders’ deficit: | |||||||||||||||||
| total stockholders’ deficit | -10,985,000 | ||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ deficit | 230,279,000 |
We provide you with 20 years of balance sheets for Cytek BioSciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Cytek BioSciences. Explore the full financial landscape of Cytek BioSciences stock with our expertly curated balance sheets.
The information provided in this report about Cytek BioSciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.